Artemis Therapeutics Receives Orphan Drug Designation From U.S. Food And Drug Administration For Artemisone For The Treatment Of Malaria

Print More
Artemis Therapeutics, Inc. (PRNewsfoto/Artemis Therapeutics, Inc.)

NEW YORK, Nov. 6, 2017 /PRNewswire/ -- Artemis Therapeutics, Inc. (OTCQB: ATMS), ("Artemis" or the "Company"), a pharmaceutical company developing new therapies for the treatment of life-threatening infectious diseases, today

Comments are closed.